Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same
Inventors
Yoon, Seong Jun • JUN, Soo Youn • Paik, Hyoun Rok • Son, Jee Soo • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11458177-B2
Publication Date
2022-10-04
Expiration Date
Abstract
The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by administering the pharmaceutical composition.
Core Innovation
Siphoviridae bacteriophage Ent-FAP-4 (KCTC 12854BP) is disclosed, including its genome represented by the nucleic acid sequence of SEQ ID NO:1. The phage has an ability to specifically kill a bacterial strain of Enterococcus faecium and is associated with preventing and treating diseases caused by Enterococcus faecium.
The document addresses the need for a therapeutic approach for Enterococcus faecium infections, including urinary tract infections, wound infections, bacteremia, and endocarditis. It states that conventional antibiotics can have an impact on commensal bacteria and that a phage with high specificity is desirable. It further states that the antibacterial spectrum is strain-dependent.
The document states advantages of using Ent-FAP-4, including high specificity compared to antibiotics and reduced impact on commensal bacteria. Experimental support described in the document includes genome novelty, killing of 9/10 Enterococcus faecium strains, no killing of non-target species, growth inhibition in vitro, and therapeutic efficacy in animal models.
Claims Coverage
The document includes one independent claim. The claim covers administering to an animal other than a human a composition containing a specifically identified Siphoviridae bacteriophage, together with specifying the phage genome sequence and deposition, and limiting the diseases to urinary tract infections, wound infections, bacteremia, or endocarditis.
Administering non-human animal composition containing Ent-FAP-4 for Enterococcus faecium disease suppression
Administering to an animal other than a human a composition comprising Siphoviridae bacteriophage Ent-FAP-4 to suppress diseases caused by a bacterial strain of Enterococcus faecium and alleviate a pathological condition of the diseases.
Phage specified by ability to specifically kill Enterococcus faecium strain
Using Ent-FAP-4 that has an ability to specifically kill the bacterial strain of Enterococcus faecium.
Phage genome sequence SEQ ID NO:1 and deposition KCTC 12854BP
Providing Ent-FAP-4 with the genome represented by the nucleic acid sequence of SEQ ID NO:1 and deposited as accession number KCTC 12854BP.
Disease scope limited to urinary tract, wound, bacteremia, and endocarditis
Limiting the diseases to urinary tract infections, wound infections, bacteremia, or endocarditis.
The independent claim is directed to a non-human animal administration method using a Siphoviridae bacteriophage Ent-FAP-4 composition, where the phage is defined by its specific Enterococcus faecium strain-killing ability, its genome sequence SEQ ID NO:1, and deposition as KCTC 12854BP, for diseases limited to urinary tract infections, wound infections, bacteremia, or endocarditis.
Stated Advantages
High specificity compared with antibiotics.
Reduced impact on commensal bacteria.
Strain-dependent antibacterial spectrum.
Documented Applications
Preventing and treating diseases caused by Enterococcus faecium, including urinary tract infections, wound infections, bacteremia, and endocarditis.
Use in animal models is documented, including survival/growth outcomes in chicks and mice following Enterococcus challenge/infection.
Interested in licensing this patent?